Management from 2016 Manny Award winners and finalists weigh in on various industry topics presented to them by Med Ad News.
Rivals Novo Nordisk and Sanofi have won U.S. approval for new combination drugs to treat diabetes, sparking a fresh battle for sales in a fiercely competitive market.
The National Institute for Clinical Excellence has finally given backing for the NHS’ approval of Perjeta for human epidermal growth factor receptor 2-positive breast cancer.
Sanofi and Regeneron will continue a large clinical outcomes study for the injectable cholesterol-lowering drug Praluent, confounding hopes of an early win.
It’s important for the pharma industry to take a closer look at the benefits of going beyond the pill and leveraging technology to deliver better care resulting in better patient outcomes and potential savings to the overall health system.
The internal watchdog at the U.S. Department of Health and Human Services warned the office tasked with administering federal health insurance programs that Mylan NV’s EpiPen was improperly classified as a generic drug in 2009, Senator Charles Grassley said.
Privately held drugmaker Kaleo Inc. announced plans for a U.S. relaunch of its Auvi-Q injector for life-threatening allergic reactions in the first half of 2017.
Britain’s healthcare cost agency NICE plans to fast-track its recommendations for the most cost-effective new drugs.
Nearly three-quarters of U.S. dermatologists received payments worth a collective $34 million from drug companies in 2014, according to a new analysis of a public database.
Robert Mulroy, CEO of Merrimack Pharmaceuticals, has resigned his position as part of a corporate restructuring move that will result in a 22 percent workforce reduction.